News Focus
News Focus
icon url

hoffmann6383

12/07/22 1:29 PM

#545333 RE: HyGro #545332

Are we giving facts without cites or giving a wish list of what shorts hoped had occurred? Seems to be the later as this narrative is 100% bullshit.

have a great one gro!
Bullish
Bullish
icon url

SkyLimit2022

12/07/22 1:32 PM

#545335 RE: HyGro #545332

I wouldn’t be concerned about the trial design or protocols—the trial was conducted by clinical trial experts!

I suggest doing some research about these interesting facts:









https://connect.uclahealth.org/2021/03/22/ucla-received-590-million-in-nih-funding-second-highest-total-for-academic-medical-centers-in-2020/

https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847
Bullish
Bullish
icon url

kabunushi

12/07/22 1:39 PM

#545339 RE: HyGro #545332

So you think proper dosage is a big issue in ph 3 clinical trials? I don't think so. I'm no great expert but I think that ph 3 trials are assumed to be done using optimal doses.
icon url

SkyLimit2022

12/07/22 1:40 PM

#545340 RE: HyGro #545332

The data collected over many years at 94 trial sites were confirmed by JAMA Oncology!





https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847
Bullish
Bullish
icon url

Dr Bala

12/07/22 1:53 PM

#545345 RE: HyGro #545332

The P3 results are outstanding. Thanks, HyGro.

icon url

SkyLimit2022

12/07/22 2:45 PM

#545375 RE: HyGro #545332

Double dosing? Interesting—Could you please provide the source for that assertion? I am very curious to read the document where you got that peculiar detail from. Thanks!

https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847
Bullish
Bullish